Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Summit Technology (BEAM) -- Ignore unavailable to you. Want to Upgrade?

To: John Binford, Jr. who wrote (850)	4/23/1998 8:54:00 PM
From: yosid	Read Replies (2) \| Respond to of 1386

Please understand! My problem with VISX (and Summit for that matter) is that they waisted valuable time in-fighting amongst themselves when the real competition should have been for leadership from laser sales and the generation of royalties. You don't fight when you have a Monopoly!! Look how the Net stocks have surged with more risk inherent. Here is a product that borders on revolutionary, and we can't get a consistent price bounce worth DIT. Competition now may kill both companies, and I use Summit as an example. After their approval, Summit flew out in front, but the arrival of VISX has kicked the hell out of them, and they have not recovered to date. If VISX thinks it can't happen to them, just read the ratings of the machines being tested and the projected sales prices against the price of a VISX laser (the new generation). I'll tell you something for sure. The LVC's will go with the machine that is in their best interest; forget brand loyalty. LCAV purchased Visx lasers when Summit stockholders owned near 20% of the company. As for the patents, again remember. Summit has not lost a patent fight. The FTC is challenging various patent rights of VISX, and if Visx loses their royalty contention, they will be putting out some some big bucks.